Business context and reporting period
This filing is Stellar Biotechnologies, Inc.’s unaudited Form 10-Q for the three months ended December 31, 2015, the first quarter of its fiscal 2016 year. The request identifies Edesa Biotech, Inc., but the filing names Stellar Biotechnologies, Inc.; verify the company and filing match. Stellar develops, manufactures and commercializes Keyhole Limpet Hemocyanin (KLH) for biotechnology, pharmaceutical and research customers. Its shares began trading on Nasdaq in November 2015.
Financial results and liquidity
| Metric | Three months ended Dec. 31, 2015 | Prior-year quarter |
|---|---|---|
| Revenue | $488,160 | $212,661 |
| Net loss | $1,629,803 | $1,343,477 |
| Loss per share, basic and diluted | $0.19 | $0.17 |
| Cash used in operations | $1,174,545 | $1,285,544 |
| Investing cash flow | $(176,648) | $402,840 provided |
| Financing cash flow | $1,368,260 provided | $28,719 provided |
Product sales were $456,160, up from $152,661; contract services revenue was $32,000, down from $60,000. Costs of sales and contract services were $312,063, versus $95,925. Revenue less this cost line was $176,097 (about 36% of revenue), compared with $116,736 (about 55%) in the prior-year quarter; this is not a complete company-wide margin measure because aquaculture costs and other expenses are reported separately.
Total expenses were $1,795,514, up from $1,538,075. Research and development expense fell to $288,849 from $418,821, while general and administrative expense rose to $1,109,689 from $942,153. The loss before tax was $1,622,603; income tax expense was $7,200.
At December 31, 2015, cash and cash equivalents were $3,887,550 and short-term investments were $5,016,800. Working capital was $8,968,877 and total assets were $10,354,493. Current liabilities were $723,675, consisting of accounts payable and accrued liabilities; the balance sheet reports no warrant liability or deferred revenue at quarter-end. No debt balance is reported. Cash and cash equivalents declined $67,953 during the quarter.
Material changes versus the prior comparable period
- Revenue increased $275,499, principally from increased product sales, greater sales volume and custom-manufactured products.
- Net loss widened by $286,326. Management attributed the change primarily to the warrant fair-value movement: a $211,956 loss in 2015 versus a $139,556 gain in 2014. This item was noncash.
- Operating cash use improved by $110,999; warrant exercises and other financing provided $1,368,260, and 464,000 common shares were issued during the quarter.
- Research and development spending declined as the company shifted focus toward manufacturing in response to customer demand. General and administrative costs rose, including Nasdaq listing fees, compensation, share-based compensation and investor relations costs.
- Revenue concentration shifted geographically: Asia represented 61% of revenue versus 31% a year earlier, while Europe represented 37% versus 54%. Three customers accounted for 85% of revenue, compared with two customers accounting for 71%.
Outlook, risks and unusual items
Management said available financial resources were expected to support initiatives for at least 12 months and that working capital was sufficient for present requirements, including contractual obligations and anticipated research and development spending. The company nevertheless expected continued losses and said it might need additional capital; no new financing commitment was secured. Possible funding sources include product and service revenue, grants, collaborations, licensing, equity and debt financing. No formal revenue or earnings guidance was provided.
Risks and commitments include customer and geographic concentration, foreign-exchange exposure, reliance on future financing, and execution of KLH commercialization plans. The company reported approximately $364,000 of contract research organization and consultant commitments and an estimated $13,000 of contractor commitments, expected to be fulfilled within 12 months. Future minimum lease payments totaled $575,000. A KLH-related license includes contingent development and financing milestones of up to $6.02 million and sales milestones totaling $57.025 million; no milestones other than a previously paid $100,000 financing milestone had been met. The company reported no material legal proceedings, no material change in previously disclosed risk factors, and effective disclosure controls.
Most important facts to verify
- Confirm the apparent issuer mismatch: the filing is for Stellar Biotechnologies, Inc., not Edesa Biotech, Inc.
- Verify the quarter-end liquidity and management’s at-least-12-month runway assessment against subsequent cash use, financing and operating results.
- Assess whether increased product sales are repeatable, given customer concentration and the significant contribution from custom manufacturing and Asian sales.
- Review the causes and cash versus noncash components of the net loss, including warrant fair-value changes and foreign-exchange effects.
- Check the status of the expired collaboration agreement, KLH license milestones, lease commitments and any subsequent financing or commercial agreements.